A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2015
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SWITCH
- 22 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Feb 2014 Primary endpoint 'Progression-free-survival' has not been met.
- 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History